# A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

> **NCT01846611** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 581 (actual)

## Conditions studied

- Ovarian Neoplasms
- Peritoneal Neoplasms
- Fallopian Tube Neoplasms

## Interventions

- **DRUG:** Trabectedin
- **DRUG:** DOXIL
- **DRUG:** Dexamethasone
- **DRUG:** DOXIL

## Key facts

- **NCT ID:** NCT01846611
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-16
- **Primary completion:** 2018-01-18
- **Final completion:** 2018-11-16
- **Target enrollment:** 581 (ACTUAL)
- **Last updated:** 2019-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01846611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01846611, "A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT01846611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*